BACKGROUND: HIV infection is associated with an increased risk of coronary artery disease, but the contribution of inflammation versus antiretroviral drugs is not well understood. Fibrinogen is an inflammatory factor associated with atherosclerosis. METHODS: A total of 1131 HIV-infected patients and 281 controls [from the Coronary Artery Risk Development in Young Adults (CARDIA) study, a population-based study of cardiovascular risk assessment] in the Study of Fat Redistribution and Metabolic Change in HIV infection (FRAM) had plasma fibrinogen levels measured. Multivariable linear regression identified factors associated with fibrinogen. RESULTS: HIV-infected patients had higher levels of fibrinogen compared with controls (males: 25 mg/dl higher, P = 0.006; females: 21 mg/dl higher, P = 0.39). Among HIV-infected persons, median levels of fibrinogen were 11% higher in patients currently using any protease inhibitor (PI) compared with those not using a PI (P < 0.0001). The strongest univariate associations were with the individual PIs, ritonavir and indinavir. Patients taking indinavir boosted with ritonavir had median fibrinogen levels 8% higher than those on indinavir alone (P = 0.049). Lower levels of fibrinogen were seen in those HIV-infected patients currently using any nonnucleoside reverse transcriptase inhibitor (NNRTI) compared to those not using an NNRTI (nevirapine -14.4%, P < 0.0001; efavirenz -7%, P = 0.0002). The associations of ritonavir, indinavir, efavirenz and nevirapine with fibrinogen levels persisted after multivariable analysis and were independent of other antiretroviral use. CONCLUSION: Protease inhibitor use is associated with elevated fibrinogen levels which may contribute to increased risk of atherosclerosis in HIV-infected patients. Conversely, NNRTI use is associated with lower fibrinogen levels which may decrease risk of atherosclerosis.
BACKGROUND:HIV infection is associated with an increased risk of coronary artery disease, but the contribution of inflammation versus antiretroviral drugs is not well understood. Fibrinogen is an inflammatory factor associated with atherosclerosis. METHODS: A total of 1131 HIV-infectedpatients and 281 controls [from the Coronary Artery Risk Development in Young Adults (CARDIA) study, a population-based study of cardiovascular risk assessment] in the Study of Fat Redistribution and Metabolic Change in HIV infection (FRAM) had plasma fibrinogen levels measured. Multivariable linear regression identified factors associated with fibrinogen. RESULTS:HIV-infectedpatients had higher levels of fibrinogen compared with controls (males: 25 mg/dl higher, P = 0.006; females: 21 mg/dl higher, P = 0.39). Among HIV-infectedpersons, median levels of fibrinogen were 11% higher in patients currently using any protease inhibitor (PI) compared with those not using a PI (P < 0.0001). The strongest univariate associations were with the individual PIs, ritonavir and indinavir. Patients taking indinavir boosted with ritonavir had median fibrinogen levels 8% higher than those on indinavir alone (P = 0.049). Lower levels of fibrinogen were seen in those HIV-infectedpatients currently using any nonnucleoside reverse transcriptase inhibitor (NNRTI) compared to those not using an NNRTI (nevirapine -14.4%, P < 0.0001; efavirenz -7%, P = 0.0002). The associations of ritonavir, indinavir, efavirenz and nevirapine with fibrinogen levels persisted after multivariable analysis and were independent of other antiretroviral use. CONCLUSION: Protease inhibitor use is associated with elevated fibrinogen levels which may contribute to increased risk of atherosclerosis in HIV-infectedpatients. Conversely, NNRTI use is associated with lower fibrinogen levels which may decrease risk of atherosclerosis.
Authors: Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak Journal: J Acquir Immune Defic Syndr Date: 2008-06-01 Impact factor: 3.731
Authors: Grace A Lee; Tara Seneviratne; Mustafa A Noor; Joan C Lo; Jean-Marc Schwarz; Francesca T Aweeka; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld Journal: AIDS Date: 2004-03-05 Impact factor: 4.177
Authors: G D Friedman; G R Cutter; R P Donahue; G H Hughes; S B Hulley; D R Jacobs; K Liu; P J Savage Journal: J Clin Epidemiol Date: 1988 Impact factor: 6.437
Authors: Rebecca Scherzer; Wei Shen; Steven B Heymsfield; Cora E Lewis; Donald P Kotler; Mark Punyanitya; Peter Bacchetti; Michael G Shlipak; Carl Grunfeld Journal: Obesity (Silver Spring) Date: 2010-06-10 Impact factor: 5.002
Authors: A Ross Eckard; C T Longenecker; Y Jiang; S M Debanne; D Labbato; N Storer; G A McComsey Journal: HIV Med Date: 2014-03-20 Impact factor: 3.180
Authors: Joseph A C Delaney; Rebecca Scherzer; Mary L Biggs; Michael G Shliplak; Joseph F Polak; Judith S Currier; Richard A Kronmal; Christine Wanke; Peter Bacchetti; Daniel O'leary; Phyllis C Tien; Carl Grunfeld Journal: AIDS Date: 2010-09-10 Impact factor: 4.177
Authors: Rebecca Scherzer; Steven B Heymsfield; Daniel Lee; William G Powderly; Phyllis C Tien; Peter Bacchetti; Michael G Shlipak; Carl Grunfeld Journal: AIDS Date: 2011-07-17 Impact factor: 4.177
Authors: Jason Baker; Woubeshet Ayenew; Harrison Quick; Katherine Huppler Hullsiek; Russell Tracy; Keith Henry; Daniel Duprez; James D Neaton Journal: J Infect Dis Date: 2010-01-15 Impact factor: 5.226